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Abstract 
Chronic Hepatitis C Virus, or HCV, affects 120-150 million 
people worldwide. HCV causes liver disease and there is not a 
vaccine or an effective treatment1. Previous research 
indicated that compounds SL209 and SL205 inhibited the 
dimerization of core, the capsid protein of HCV responsible for 
assembling and releasing the infectious particle2. Current 
research is focused on testing the effect that the structure of 
these compounds has on their bioactivities, so analogues with 
similar structures to SL209 and SL205 are being synthesized.  
 
Inhibiting Core Dimerization 
Core is the capsid protein of HCV that assembles and 
packages the RNA genome of HCV, which then forms the 
viral nucleocapsid. Core is involved in the life cycle of HCV, 
including the assembly and release of the infectious particle. 
Inhibiting core could interfere with uncoating the viral particle, 
could prevent the formation of new viral particles, and could 
destabilize the entire virus particle. It was previously found that 
compounds SL209 and SL205 inhibit core dimerization, which is 
important because core has to dimerize to make HCV 
infectious2.  
 
Introduction 
HCV is a bloodborne virus that can either be acute or chronic. 
Acute HCV usually is not life threatening and is usually 
asymptomatic. People with acute HCV can recover without 
treatment. Millions of people develop chronic HCV, which 
causes liver disease, such as liver cirrhosis, liver fibrosis, and 
even liver cancer. There is no vaccine and treatment is mostly 
ineffective. HCV can be contracted through needle sharing, 
inadequate sterilization of medical equipment, blood 
transfusions with untested blood, as well as sexually1.  
Analogue Type A 
Analogue A compounds are being synthesized to test the 
effect of the size of the D-ring and the effect of substitutions 
on the A-ring on bioactivity. Some of these analogues will test 
how the D-ring size and angle to the aromatic core effect the 
bioactivities of compounds SL209 and SL205. Other analogues 
will test the significance of adding a methoxy group  to 
carbon 5 on the A-ring to the bioactivities of SL209 and SL205.  
 
Synthesizing Analogue B1 
Analogues B and C 
Analogues B and C are being synthesized to test the 
significance of the D-ring in SL209 and SL205.  Type B 
analogues have their D-ring reduced from a six-membered 
ring to a five-membered ring. Type C have the D-ring 
removed altogether.  These changes can effect the activity 
of the compounds by flattening the core, while retaining its 
chirality.  
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